PRDM14 is overexpressed in various cancers and can regulate cancer phenotype under certain conditions. Inhibiting PRDM14 expression in breast and pancreatic cancers has been reported to reduce cancer stem-like phenotypes, which are associated with aggressive tumor properties. Therefore, PRDM14 is considered a promising target for cancer therapy. To develop a pharmaceutical treatment, the mechanism and interacting partners of PRDM14 need to be clarified. Here, we identified the proteins interacting with PRDM14 in triple-negative breast cancer (TNBC) cells, which do not express the three most common types of receptor (estrogen receptors, progesterone receptors, and HER2). We obtained 13 candidates that were pulled down with PRDM14 in TNBC HCC1937 cells and identified them by mass spectrometry. Two candidates-glucoseregulated protein 78 (GRP78) and heat shock protein 90-a (HSP90a)-were confirmed in immunoprecipitation assay in two TNBC cell lines (HCC1937 and MDA-MB231).
transcription regulator required for maintaining pluripotency, and a required component for epigenetic reprogramming. [1] [2] [3] [4] [5] overexpression in several cancers has been shown to be related to cancer properties such as proliferation, drug resistance, and differentiation. [6] [7] [8] [9] We have previously reported that knockdown of PRDM14 expression decreased cancer stem-like phenotypes, which are considered responsible for cancer initiation and progression in breast and pancreatic cancer cells. 9, 10 Because siRNA-based therapy targeting PRDM14 by tail vein injection decreased xenograft tumor and metastasis in mice, PRDM14 is considered a promising target for the treatment of these cancers. However, the working mechanism of PRDM14 in cancers is mostly unknown.
PRDM14 consists of a PR domain and six C2H2-type zinc finger motifs. The PR domain is related in sequence to a SET methyltransferase domain but histone methyltransferase activity is found in only a subset of the PRDM family. 11 Although PRDM14 indirectly associates with a methyltransferase process by recruiting a partner, innate methyltransferase activity has not been detected in PRDM14. 4 The zinc finger motif is a DNA-binding entity 12 and, in some cases, also interacts with RNA, protein, and lipid. [13] [14] [15] [16] [17] PRDM14 was reported to interact with proteins by IP and/or pull-down, including components of PRC2 and KLF2 in ES cells, and TET enzymes in epiblast-like cells.
These interactions regulate pluripotency, differentiation, and reprogramming. 4, 18, 19 However, binding partners of PRDM14 were not identified in cancer cells.
Breast cancer is one of the most common cancers worldwide. 20 Breast cancers that express one or more of the three most common types of receptor (estrogen receptors, progesterone receptors, and HER2) can be treated with hormone and/or trastuzumab therapies to achieve a good prognosis. However, TNBC, which lack all three types of receptor, are often more aggressive with poor prognosis and are more difficult to treat. We have reported that inhibition of PRDM14 decreased s.c. xenografted tumor growth and metastasis of TNBC cell lines, suggesting that PRDM14 is a good target for treating TNBC in patients. 10 Elucidation of the binding partners of PRDM14 will help elucidate the mechanism whereby PRDM14 regulates cancer phenotypes, which could contribute to the development of a less costly treatment for patients with these cancers.
Heat shock proteins are highly conserved and are induced in response to several stimuli including environmental stress. HSPs are multifunctional; they possess chaperone activity, 21 inhibit apoptosis by associating with factors of the apoptotic machinery, 22 and contribute to cell survival by regulating the stability or degradation of selected proteins. 23, 24 In cancer cells, HSPs are highly expressed and further increased after stimulation. Moreover, HSP expression correlates with tumor growth, metastasis, and chemotherapy resistance.
Thus, HSPs are an emerging target for cancer treatment. 25, 26 HSP90a is the most prominent member of the HSP90 family and many client proteins have been identified. [27] [28] [29] The client proteins cover various cellular processes and include cancer-associated proteins, such as tumor suppressor proteins and mediators of invasion, metastasis, and angiogenesis. 30, 31 GRP78 is also known as BiP and belongs to the HSP70 family. Its expression is known to increase during ER stress, which takes place when unfolded and/or misfolded proteins accumulate in the ER lumen. GRP78 works as a protein chaperone to mitigate potential damage from the unfolded species. 32 In cancer cells, ER stress from microenvironmental factors, such as hypoxia and acidosis, upregulates GRP78 expression. 33 In breast cancer, overexpressed GRP78 inhibits cell death by elevating anti-apoptotic proteins 34 and promotes autophagy, which enhances survival and drug resistance. 35 To elucidate the molecular mechanism of PRDM14 in cancer cells, we carried out Halo pull-down from Halo-PRDM14 transduced TNBC HCC1937 cells, followed by mass spectrometry to identify binding partners. For the binding candidate proteins, we provided SPR analysis supporting that PRDM14 directly bound with HSP90a and GRP78. Furthermore, we carried out a NanoBRET binding assay to assess protein-protein interactions in living cells, 36 which can be made available for screening of binding inhibitors in the future. Moreover, we carried out experiments using HSP90 and GRP78 inhibitors to assess their effects on PRDM14-mediated cell processes.
| MATERIALS AND METHODS

| Cell culture
The 293T cell line was purchased from ATCC (Manassas, VA, USA).
The cell was identified by the cell banks using short tandem repeat analysis. The cells were cultured in DMEM (Thermo Fisher Scientific, San Jose, CA, USA) containing 10% FBS (GE Healthcare, Uppsala, Sweden). Two TNBC cell lines, HCC1937 and MDA-MB231 cells, were obtained and cultured as described previously. 10 All cell lines were incubated at 37°C in a humidified atmosphere containing 5% CO 2 .
| Plasmid construction
A DNA fragment encoding PRDM14-DC (amino acids 1-412) was inserted into pReceiver-Lv110 vector (GeneCopoeia, Rockville, MD, USA) to produce the plasmid encoding Halo-PRDM14-DC. For production of proteins tagged with NLuc at either the N-or C-terminus, a DNA fragment containing the ORF sequence was inserted into pFN31K or pFC32K NLuc CMV-neo Flexi vector (Promega, Madison, WI, USA) at the SgfI and PmeI sites, respectively. The insert sequences of HSP90a and GRP78 are the same as those of FHC25301 and FHC10475, respectively (Kazusa DNA Res. Inst., Chiba, Japan).
| Lentiviral transduction
The plasmid vectors used were HaloTag fusion human PRDM14 (Halo-PRDM14; EX-W1089-Lv110; GeneCopoeia), and HaloTag fusion EGFP (Halo-con; EX-EGFP-Lv110; GeneCopoeia). HCC1937 and MDA-MB231 cells were transduced using the Lenti-pack HIV Expression Packaging Kit (GeneCopoeia). 10 shRNA-transduced HCC1937 cells (control shRNA and two anti-human PRDM14 shRNAs [sh#1 and sh#3]) were prepared as previously described. 10 
| HaloTag pull-down and mass spectrometry
The HaloTag pull-down assay was carried out using HaloTag Mam- 
| Immunoprecipitation
Immunoprecipitation was carried out using HCC1937 and MDA- 
| Protein analysis by automated capillary electrophoresis and immunodetection
Protein levels were quantified using an automated capillary electrophoresis and immunoassay system, Wes (ProteinSimple, Santa Clara, CA, USA) or western blotting as described previously. 9 We used the following primary antibodies: PRDM14 (ab187881), HSP90a (ab2928), GRP78 (ab21685), and caspase-14 (ab174847) from Abcam Inc., GAPDH (#5174) and c-catenin (#2309) from Cell Signaling Technology Inc., and Halo (G928A) from Promega. Secondary antibody used was TrueBlot HRP-conjugated anti-rabbit antibody (Rockland) for immunoprecipitated samples.
| NanoLuc fusion protein detection
NanoLuc fusion proteins were analyzed by luciferase activity. The lysates of NLuc fusion protein-transfected 293T were separated by non-reducing SDS-PAGE and transferred to PVDF membrane. The transferred membrane was treated with the substrate for NLuc and luminescence was detected with an ImageQuant Las-4010 system (GE Healthcare).
| Proteins
We used the following proteins for SPR analysis: Human PRDM14 (H00063978-P01, GST-Tag at N-terminus; Abnova Inc., Taipei, Tai 
| Surface plasmon resonance analysis
Interactions between putative partner proteins and PRDM14 were investigated by SPR analysis using a Biacore X100 plus instrument 
| NanoLuc luciferase-based bioluminescence resonance energy transfer
We carried out NanoBRET assays using a NanoBRET Nano-Glo For the initial screening, we carried out the NanoBRET assay with Halo-PRDM14 and the proteins tagged with NLuc at either N-or C-terminus and chose the combination that yielded a larger BRET ratio. To validate a NanoBRET assay without known inhibitors, we ascertained assay specificity by carrying out a simplified donor saturation assay. 1:1, 1:10, 1:100, and 1:1000 dilutions of NLuc relative to HaloTag DNA were used. If the protein-protein interactions were real, the donor saturation assay curve would reach an asymptote, whereas a negative control would not.
| Inhibitors
DMAG-17, HSP990, VER155008, and HA15 were purchased from Selleck Chemicals (Houston, TX, USA). Cells were incubated for 24 hours, and were then treated with inhibitors for 24 hours. DMSO was used as a solvent and the negative control for these experiments. The proliferation assay was carried out using the Cell Counting Kit-8 (Dojindo, Kumamoto, Japan). Isolation of SP cells and cell surface marker analyses were carried out using a FACSAria or FACS-Verse flow cytometer (BD Biosciences, San Jose, CA, USA), as previously described. 9 2.12 | siRNA transfection Two DNA-chimeric siRNAs targeting the coding region of PRDM14 (PRDM14_1082-1104 and PRDM14_1504-1526; si#2 and si#3, respectively) as well as a negative control DNA-chimeric siRNA (siNEGA) were purchased from RNAi Inc. (Tokyo, Japan). 9 Cells were transfected with them using the Lipofectamine RNAiMAX Reagent (Thermo Fisher Scientific).
| RESULTS
| Identification of proteins interacting with PRDM14 in TNBC cells
To identify intracellular protein partners of PRDM14 in TNBC cells, we carried out Halo pull-down assays followed by mass spectrome- Halo pull-down samples from HCC1937 and MDA-MB231 cells were additionally analyzed by immunodetection. HSP90a, GRP78, and c-Catenin were detected, but Caspase-14 was not (Figure 2A ).
Subsequently, we carried out an immunoprecipitation assay using antibodies for HSP90a, GRP78, or c-Catenin on Halo-PRDM14 transduced HCC1937 and MDA-MB231 cell lysates ( Figure 2B ).
Halo-PRDM14 was detected in all 3 immunoprecipitated samples from both cell lines ( Figure 2C ). Interactions of Halo-con and the proteins were not observed in either the Halo pull-down or the immunoprecipitation assays ( Figure S1 ). These results suggest that HSP90a, GRP78, and c-Catenin interacted with PRDM14 in TNBC cells.
| Confirmation of direct interactions between PRDM14 and selected proteins by SPR analysis
To determine whether interactions between PRDM14 and the identified proteins were direct or indirect, we carried out SPR experiments using a Biacore instrument. GST-PRDM14 protein was captured by an anti-GST antibody-immobilized sensor chip, which was used as bait for the candidate proteins. Stable binding of GRP78, HSP90a, and c-Catenin to GST-PRDM14 was detected ( Figure 3A ). Stable binding between PRDM14 and Caspase-14 was not detected ( Figure 3A) , which agrees with the immunodetection data from Halo pull-down samples (Figure 2A ). Next, we carried out kinetic analysis using data from different concentrations of the two heat shock proteins (GRP78 and HSP90a) to assess the equilibrium dissociation constant (K D ) values ( Figure 3B ). K D values of GRP78 and HSP90a with PRDM14 were 3.28 9 10 À8 and 5.59 9 10 À7 mol/L, respectively, F I G U R E 1 Halo pull-down assay followed by mass spectrometry. Halo pull-down assay was carried out using Halo-PRDM14transduced MDA-MB231 and HCC1937 cells. Pull-down samples were analyzed by SDS-PAGE detected by silver stain. The 4 bands in the enlarged view (arrowheads) were analyzed by mass spectrometry suggesting they directly bind with relatively high affinity. To identify the region of PRDM14 that binds to the proteins, we carried out kinetic analysis with GST-PRDM14-DC protein, which lacks the C-terminal region including the zinc finger motifs ( Figure 3C ). Interactions between the chaperone proteins and PRDM14-DC were not detected ( Figure 3D ). We confirmed that PRDM14-DC protein bound other proteins by SPR analysis (Figure S2 ). These results indicate that PRDM14 binds directly to GRP78 and HSP90a, and the binding requires the C-terminus of PRDM14.
| Interactions between PRDM14 and selected proteins assessed by intracellular NanoBRET analysis
To validate the protein-protein interaction of PRDM14 with HSP90a and GRP78 in vivo, we carried out NanoBRET analysis ( Figure 4A ). GRP78, glucose-regulated protein 78; HSP, heat shock protein the assay. 36 293T cells were co-transfected with Halo-PRDM14 and NLuc fusion HSP90a or GRP78 (tagged with NLuc at either the N-or C-terminus) ( Figure 4B ). We chose HSP90a-NLuc and NLuc-GRP78 because they yielded a larger BRET ratio than the opposite configurations in preliminary experiments with Halo-PRDM14 (Figure S3A) . The donor saturation assay curves of HSP90a-NLuc and NLuc-GRP78 with Halo-PRDM14 reached saturation ( Figure 4C ).
The curves with Halo-PRDM14-DC and Halo-con did not reach saturation ( Figures 4D and S3B,C) . These results also indicate the interactions of PRDM14 with HSP90a and GRP78 require the C-terminal region of PRDM14 in living cells.
To determine whether PRDM14 expression is regulated by the molecular chaperones GRP78 and HSP90a, two TNBC cell lines were transfected with HSP90a-NLuc or NLuc-GRP78 alone.
PRDM14 expression was not increased by the transfection of
HSP90a or GRP78 ( Figure S3D ). In addition, Halo-PRDM14 induction had no impact on the expression of HSP90a or GRP78 ( Figure S3E) . These results suggest that the examined binding partners do not affect each other's expression.
| Effect of inhibitors on HSP90a and GRP78
To determine the physiological relevance of the interactions between PRDM14 and HSP90a or GRP78, we used HSP90 and GRP78 inhibitors. HCC1937 and MDA-MB231 cells were treated with 2 HSP90 inhibitors, 17DMAG (3 lmol/L) and HSP990 (1 lmol/ L), an HSP70 family (HSP70, HSC70, and GRP78) inhibitor, VER155008 (100 lmol/L), and a GRP78 inhibitor, HA15 (100 lmol/ L). PRDM14 expression was not changed by the inhibitors ( Figure S4A ). Proliferation of HCC1937 cells was significantly decreased by the inhibitors (P < .05) ( Figure 5A ). Combination of HA15 and PRDM14 knockdown reduced proliferation in both shPRDM14-transduced HCC1937 cells (sh#1 and sh#3) as compared with that in control shRNA-transduced cells (P < .01) ( Figure 5B ).
Decreased proliferation in HA15-treated, PRDM14 knockdown cells was also confirmed in DNA-chimeric siRNA-transfected HCC1937
and MDA-MB231 cells (P < .05) ( Figure S4B ). Next, we assessed the effects of the inhibitors on the numbers of breast cancer stem-like CD24 À CD44 + and SP cells. In HCC1937 cells, two HSP90 inhibitors Figure 5C ), whereas VER155008 and HA15 did not ( Figure S4C ). Aside from VER155008, all inhibitors decreased the proportion of SP cells in HCC1937 cells (P < .01) ( Figure 5D ). The inhibitors did not decrease the number of CD24 À CD44 + and SP cells in MDA-MB231 ( Figure S4D,E) . Subsequently, shRNA-transduced HCC1937 cells were treated with the inhibitors. The number of CD24 À CD44 + cells in shPRDM14 was significantly reduced as compared with that in sh control cells (P < .001) ( Figure 5E ), as previously reported. 10 The inhibitors did not significantly change cell population in shPRDM14 cells ( Figure 5E ). The number of SP cells in shPRDM14 was significantly reduced as compared with that in sh control cells (P < .001) ( Figure 5F ) as we have previously reported. 10 HSP90 inhibitors did not change the number of SP cells, whereas the GRP78 inhibitor HA15 significantly decreased SP cell number in shPRDM14 as compared with that of the control (P < .05) ( Figure 5F ).
| DISCUSSION
PRDM14 is overexpressed and regulates cancer properties in some cancers including TNBC, which is aggressive and difficult to treat.
Because silencing PRDM14 expression in the cancers decreases cancer stem-like phenotypes including tumor formation and metastasis, 9, 10 PRDM14 is considered a promising target for cancer therapy.
Identifying the binding partners of PRDM14 in cancers may contribute to the development of inhibitors targeting the PRDM14 working mechanism. We identified HSP90a and GRP78 as direct binding partners of PRDM14 in TNBC cells, whereas the binding patterns of PRDM14 with the other candidates are still under investigation.
Our data show that PRDM14 directly interacts with two heat shock proteins, GRP78 and HSP90a, and the interactions require the C-terminal region including the zinc finger motifs, which can interact with DNA, RNA, protein, and lipid. Many reports have shown that overexpression of other C2H2 zinc finger-containing proteins is related to several processes such as cell proliferation, invasion, migration, and drug resistance resulting in tumor progression for various cancers. [37] [38] [39] [40] Moreover, a relationship between zinc finger proteins and the heat shock response has been reported; 41, 42 a zinc finger protein ZC3H11 binds to mRNAs encoding heat-shock protein homologues and is required for stabilization of them after heat shock in Trypanosoma brucei. 42 Although we observed that PRDM14 induced by transfection did not change the expression of HSP90a or GRP78 and have been used in clinical trials. 26, 43, 44 HSP90 inhibitors significantly decreased the number of breast cancer stem-like CD24 À CD44 + ( Figure 5C ) and SP cells ( Figure 5D ) in HCC1937.
This reduction in cell number by the inhibitors was lower than that by PRDM14 knockdown. The inhibitors did not decrease cell population in shPRDM14 cells ( Figure 5E,F) , which suggests that HSP90a may be partly associated with regulation of cancer stemness by PRDM14. Interestingly, an HSP90 inhibitor is reported to be specific to cancer cells; it reduced the number of HSP client proteins in cancer cells, but had no effect in normal cells. The difference seems to be caused by the conformation of the HSP90 complex. 26, 28, 45 For example, HSP90 complexed with wild-type p53, which is a shortlived protein, is transiently activated and maintains protein homeostasis in normal cells. In contrast, most mutant p53 molecules extend their interaction with the complex, which leads to prevention of dynamic regulation in cancer cells. 45 Some HSP90 inhibitors seem to prevent an abnormal conformation of the HSP90 complex.
PRDM14 is overexpressed in several cancers including TNBC, whereas no or little expression is observed in normal mature tissues.
Moreover, our data show that PRDM14 directly interacts with
HSP90a and that HSP90 inhibitors do not decrease CD24 À CD44 + and SP cells in shPRDM14-transduced HCC1937 cells. PRDM14 may affect the roles of HSP90 in cancer regulation and the specificity of an HSP90 inhibitor in cancer cells. The GRP78 inhibitor HA15 significantly decreased proliferation in the PRDM14 knockdown TNBC cell lines as compared with that in control cells ( Figure 5B ), whereas PRDM14 knockdown alone did not decrease proliferation, as previously reported. 10 Moreover, HA15 significantly decreased SP cell numbers in both control and PRDM14 knockdown HCC1937 cells ( Figure 5D,F) . These results suggest that both PRDM14 and GRP78 regulate cancer phenotypes, and that the combination of PRDM14 knockdown and HA15 is useful for treatment.
Although GPR78 is reported to be overexpressed in breast cancer stem-like CD24 À CD44 + cells, 46 the inhibitors did not have an effect on the number of CD24 À CD44 + cells. Because VER155008 also inhibits other members of the HSP70 family, its effects may differ from that of the GRP78 inhibitor HA15, suggesting the importance of direct interaction between PRDM14 and GRP78. However, regulation of cancer stemness by these inhibitors with PRDM14 is a complicated process, as shown by the effects of these inhibitors on CD24 À CD44 + and SP cells in MDA-MB231 cells ( Figure S4D,E) , and the effect of GRP78 inhibitors on CD24 À CD44 + cells in HCC1937 cells ( Figure S4C ). Nevertheless, our results suggested that HSP90 and GRP78 participate in regulation of cancer stemness by PRDM14. In addition, combination treatment with both inhibitors and PRDM14 knockdown may be especially effective for treatment.
PRDM14 is specifically expressed in primordial germ cells and ES cells. PRDM14 and another member of the PRDM family-PRDM1
-work as transcription factors required for primordial germ cell development. [47] [48] [49] PRDM14 is related to histone methylation by DNMT in ES cells. 4 Previously, HSP90 was reported to interact with many proteins including PRDM1 in a LUMIER (LUminescence-based Mammalian IntERactome) screening assay. 29 Although the binding of HSP90 with PRDM14 was judged insignificant in the report, it may be because of the differences in methods or the strict threshold of binding to show a positive in screening. Moreover, the inhibition of HSP90 was recently reported to modulate DNA methylation by downregulating DNMTs, which are HSP90 clients, 50 for both mRNA and protein levels in colorectal and pancreatic cancers. 51 The direct interaction of PRDM14 and HSP90 may have an important role in primordial germ cell development and/or epigenetic regulation in ES cells.
In the present study, we identified GRP78 and HSP90a as bind- 
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